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INTRODUCTION
TNF is an attractive therapeutic protein with a broad range of potent anticancer effects. This multipotent cytokine is produced mainly by inhibiting normal cell growth ( ). Its anti-tumor activity is not well defined, but depends on a variety of effects within the tumor 1 microenvironment leading to selective damage to tumor-associated vessels, activation of inflammatory and immune mechanisms, tumor cell necrosis, and tumor cell apoptosis. A new approach to overcome these problems consisted of the use of a bispecific antibody (BsAb) in which one arm is directed against tumor-associated antigen (TAA) and the other arm against TNF to target this cytokine into tumors ( ). This strategy has been applied in our 
MATERIALS AND METHODS
Cell line and culture conditions
The murine colon carcinoma MC-38 transfected with the human CEA cell line (C15.4.3 AP), kindly provided by FJ Primus, was used for all experiments. The cells were cultured in DMEM medium (Gibco Laboratories, France) supplemented with 10 heat-inactivated fetal calf % serum (Gibco Laboratories, France), glutamine (300 g/ml), fungizone (0.25 g/ml), streptomycin (100 g/ml), penicillin G (100 units/ml), and μ μ μ geneticine (0.5 mg/ml). These cells were adherent and grew as monolayers at 37 C in a humidified 5 CO incubator. Cultures were checked°% 2 for the absence of mycoplasma every month.
Tumor necrosis factor and bispecific antibody
The specific activity of recombinant human TNF (Apotech, Switzerland) was 5 10 units/mg protein as determined by cytolysis of α × 7 murine L929 cells in the presence of actinomycin D. TNF (at a concentration of 2.5 mg/ml) was stored at 80 C until use.
sAb was constructed as previously described ( ) from the anti-CEA MAb 35A7 and the MAb tnf18 directed against TNF . 25 obtain a constant dose rate of 0.5 Gy/min and monthly adapted from the Co source radioactivity decrease. Control cells were removed from 60 the incubator and placed for the same period of time under the Co source but without radiation treatment. In the combined treatment modality 60 studies, TNF was added twelve hours prior to RT.
α For tumor treatment, the radiation was delivered to the flank of anaesthetized mice simultaneously in a 12.5 cm 12.5 cm field size in vivo × at 6 Gy/fraction at a dose rate of 0.5 Gy/min (SHD of 158 cm), twice a week, for a total dose of 30 Gy. A 6 cm thick lead block with 8 circular apertures, 3 cm in diameter, was used so that only the tumours and the underlying normal tissues were exposed to the radiation. Radiation was measured using dosimetry films (RA711P, Agfa, Belgium).
All mice were anaesthetized, regardless of treatment group, to equalize the effects due to stress.
Clonogenic Assay
The colony-forming assay and growth curve analyses were used to assess the sensitivity of the CIS.4.3 AP cells to TNF . Cells were α trypsinised, washed, and plated in quintuplicate at a density of 100 per 60-mm Petri dishes. Twenty-four hours after the cells were plated to allow for cell attachment, TNF was added at concentrations ranging from 19 to 2500 U/ml. Cells were incubated at 37 C in a humidified needed to obtain 50 of the maximal effect, c is a slope factor, and R is the maximal effect. The cytotoxic effect of irradiation on
asynchronous, exponentially growing C15.4.3 AP cells was also determined by the colony-forming assay. Before irradiation, cell density was determined using appropriate dilutions (100, 300, 600, 1600 cells for 0, 2, 4, and 6 Gy, respectively), and four replicates of each dilution were plated in 60 mm Petri dishes. Cells were irradiated as described above, 24 hours after plating to allow for cell attachment prior to the administration of radiation. The TNF -containing medium was given at a concentration of 156 U/ml 12 hours before irradiation. A dose of 156 α U/ml of TNF was chosen because colony forming assays showed that this dose was sufficient to induce only partial (50 survival) cell α % growth when the cytokine was used alone. Cultures were irradiated when the drug was in the medium and were immediately returned to the incubator after irradiation. Colonies were counted after 12 days. Experimentally derived data points are the mean of three experiments. The multi-target model survival curves were fitted to the data using a least squares regression to the linear-quadratic model, S S exp (-D -D
, where D is the radiation dose, S the surviving fraction, and S a normalizing parameter.
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Tumor growth in vivo inhibition
All experiments were performed in compliance with the French guidelines for experimental animal studies. CEA transgenic mice in vivo were provided by FJ Primus ( ). 26
Two consecutive experiments were performed: Experiment I included the seven different treatment groups (group 1: NaCl, group 2: TNF , and the mean CT (GAPDH as the endogenous control, CT threshold cycles).
=
Three consecutive experiments were performed (one mouse per group at each experiment) and mean values with errors were considered for publication.
Histological analyses
Samples of explanted tumors removed after the half delivered treatment, were fixed in the Alcohol-Formalin-Acetic acid (AFA) buffer, and embedded in paraffin. For histopathology examination, sections were stained with haematoxylin and eosin and examined by light microscopy.
Semi-quantitative analysis of tumor slides included measurement of necrosis, inflammatory cells, infiltration and necrosis phenomenon.
Two consecutive experiments were performed and mean values were considered for publication.
Statistical analyses
The nonparametric Wilcoxon signed rank test was used to compare the surviving fraction between the two groups (RT alone and RT TNF 
RESULTS effect of TNF with or without radiation In vitro
The cytotoxic effects of increasing concentrations of TNF (19 to 2500 U/ml) on asynchronous, exponentially growing C15.4.3 AP cells α were determined in colony-forming assays. Cell survival followed a dose-response curve fitted to a four-parameter logistic model as described in Materials and Methods.
Cells were killed by concentrations of TNF as low as 20 U/ml ( ). The LC , defined as the concentration of drug that reduced the with TNF results in a steeper decline in cell survival due both to a higher initial slope of the dose response curve and a major decrease of the α quadratic parameter. These results suggested supra-additivity between the two treatments.
radiocurability and toxicities with combined treatment In vivo
We tested the therapeutic efficacy of the combination of TNF targeted into tumor by BsAb and radiotherapy in a syngenic model. TNF Median pre-treatment tumor volumes were 165 (71 220) mm without any statistical difference between the groups. In experiment I, no At the end of all treatments, no significant differences were found in mouse body weight between the seven groups. No diarrhea was observed in any group, suggesting the absence of digestive toxicity. Neither significant fluid retention, respiratory distress, nor other signs of toxicity were observed in any of the animals during the course of the study.
Effect of exogenous TNF on endogenous TNF mRNA levels
After one week of treatment, level of endogenous TNF mRNA was measured by real-time PCR (
). We observed a significant In conclusion, our data could be used as a solid preclinical rationale on which to base a clinical study in locally advanced digestive cancers in the near future. first week of treatment, the tumors were removed and sections of fixed samples embedded in paraffin were stained with haematoxylin and eosin.
We then performed two dedicated experiments to histological analyses with one mouse per treatment group.
